Global Hereditary Angioedema Therapeutic Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Hereditary Angioedema Therapeutic Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Hereditary Angioedema Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Intravenous
  • 1.4.3 Subcutaneous
  • 1.4.4 Oral
• 1.5 Market by Application
  • 1.5.1 Global Hereditary Angioedema Therapeutic Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Hereditary Angioedema Therapeutic Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Hereditary Angioedema Therapeutic Industry
    • 1.6.1.1 Hereditary Angioedema Therapeutic Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Hereditary Angioedema Therapeutic Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Hereditary Angioedema Therapeutic Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Hereditary Angioedema Therapeutic Market Perspective (2015-2026)
• 2.2 Hereditary Angioedema Therapeutic Growth Trends by Regions
  • 2.2.1 Hereditary Angioedema Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Hereditary Angioedema Therapeutic Historic Market Share by Regions (2015-2020)
  • 2.2.3 Hereditary Angioedema Therapeutic Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Hereditary Angioedema Therapeutic Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Hereditary Angioedema Therapeutic Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Hereditary Angioedema Therapeutic Players by Market Size
  • 3.1.1 Global Top Hereditary Angioedema Therapeutic Players by Revenue (2015-2020)
  • 3.1.2 Global Hereditary Angioedema Therapeutic Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Hereditary Angioedema Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Hereditary Angioedema Therapeutic Market Concentration Ratio
  • 3.2.1 Global Hereditary Angioedema Therapeutic Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Hereditary Angioedema Therapeutic Revenue in 2019
• 3.3 Hereditary Angioedema Therapeutic Key Players Head office and Area Served
• 3.4 Key Players Hereditary Angioedema Therapeutic Product Solution and Service
• 3.5 Date of Enter into Hereditary Angioedema Therapeutic Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Hereditary Angioedema Therapeutic Historic Market Size by Type (2015-2020)
• 4.2 Global Hereditary Angioedema Therapeutic Forecasted Market Size by Type (2021-2026)

5 Hereditary Angioedema Therapeutic Breakdown Data by Application (2015-2026)

• 5.1 Global Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)
• 5.2 Global Hereditary Angioedema Therapeutic Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 6.2 Hereditary Angioedema Therapeutic Key Players in North America (2019-2020)
• 6.3 North America Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 6.4 North America Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 7.2 Hereditary Angioedema Therapeutic Key Players in Europe (2019-2020)
• 7.3 Europe Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 7.4 Europe Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

8 China

• 8.1 China Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 8.2 Hereditary Angioedema Therapeutic Key Players in China (2019-2020)
• 8.3 China Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 8.4 China Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 9.2 Hereditary Angioedema Therapeutic Key Players in Japan (2019-2020)
• 9.3 Japan Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 9.4 Japan Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 10.2 Hereditary Angioedema Therapeutic Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 10.4 Southeast Asia Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

11 India

• 11.1 India Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 11.2 Hereditary Angioedema Therapeutic Key Players in India (2019-2020)
• 11.3 India Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 11.4 India Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Hereditary Angioedema Therapeutic Market Size (2015-2020)
• 12.2 Hereditary Angioedema Therapeutic Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Hereditary Angioedema Therapeutic Market Size by Type (2015-2020)
• 12.4 Central & South America Hereditary Angioedema Therapeutic Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 BioCryst Pharma
  • 13.1.1 BioCryst Pharma Company Details
  • 13.1.2 BioCryst Pharma Business Overview and Its Total Revenue
  • 13.1.3 BioCryst Pharma Hereditary Angioedema Therapeutic Introduction
  • 13.1.4 BioCryst Pharma Revenue in Hereditary Angioedema Therapeutic Business (2015-2020))
  • 13.1.5 BioCryst Pharma Recent Development
• 13.2 Ionis Pharma
  • 13.2.1 Ionis Pharma Company Details
  • 13.2.2 Ionis Pharma Business Overview and Its Total Revenue
  • 13.2.3 Ionis Pharma Hereditary Angioedema Therapeutic Introduction
  • 13.2.4 Ionis Pharma Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.2.5 Ionis Pharma Recent Development
• 13.3 Pharming Group
  • 13.3.1 Pharming Group Company Details
  • 13.3.2 Pharming Group Business Overview and Its Total Revenue
  • 13.3.3 Pharming Group Hereditary Angioedema Therapeutic Introduction
  • 13.3.4 Pharming Group Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.3.5 Pharming Group Recent Development
• 13.4 CSL Limited
  • 13.4.1 CSL Limited Company Details
  • 13.4.2 CSL Limited Business Overview and Its Total Revenue
  • 13.4.3 CSL Limited Hereditary Angioedema Therapeutic Introduction
  • 13.4.4 CSL Limited Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.4.5 CSL Limited Recent Development
• 13.5 Shire
  • 13.5.1 Shire Company Details
  • 13.5.2 Shire Business Overview and Its Total Revenue
  • 13.5.3 Shire Hereditary Angioedema Therapeutic Introduction
  • 13.5.4 Shire Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.5.5 Shire Recent Development
• 13.6 Attune Pharma
  • 13.6.1 Attune Pharma Company Details
  • 13.6.2 Attune Pharma Business Overview and Its Total Revenue
  • 13.6.3 Attune Pharma Hereditary Angioedema Therapeutic Introduction
  • 13.6.4 Attune Pharma Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.6.5 Attune Pharma Recent Development
• 13.7 Adverum Biotechnologies
  • 13.7.1 Adverum Biotechnologies Company Details
  • 13.7.2 Adverum Biotechnologies Business Overview and Its Total Revenue
  • 13.7.3 Adverum Biotechnologies Hereditary Angioedema Therapeutic Introduction
  • 13.7.4 Adverum Biotechnologies Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.7.5 Adverum Biotechnologies Recent Development
• 13.8 KalVista Pharma
  • 13.8.1 KalVista Pharma Company Details
  • 13.8.2 KalVista Pharma Business Overview and Its Total Revenue
  • 13.8.3 KalVista Pharma Hereditary Angioedema Therapeutic Introduction
  • 13.8.4 KalVista Pharma Revenue in Hereditary Angioedema Therapeutic Business (2015-2020)
  • 13.8.5 KalVista Pharma Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer